Background: Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increasingly used as an off-label treatment option for multiple sclerosis (MS). Objective: To investigate the effectiveness and safety of rituximab in relapsing-remitting (RR) and progressive MS. Methods: This is a multicenter, retrospective study on consecutive MS patients treated off-label with rituximab in 22 Italian and 1 Swiss MS centers. Relapse rate, time to first relapse, Expanded Disability Status Scale (EDSS) progression, incidence of adverse events, and radiological outcomes from 2009 to 2019 were analyzed. Results: A total of 355/451 enrolled subjects had at least one follow-up visit and were included in the outcome analysis. Annualized relapse rate significantly decreases after rituximab initiation versus the pre-rituximab start year in RRMS (from 0.86 to 0.09, p < .0001) and in secondary-progressive (SP) MS (from 0.34 to 0.06, p < .0001) and had a slight decrease in primary-progressive (PP) MS patients (from 0.12 to 0.07, p = 0.45). After 3 years from rituximab start, the proportion of patients with a confirmed EDSS progression was 14.6% in the RRMS group, 24.7% in the SPMS group, and 41.5% in the PPMS group. No major safety concerns arose. Conclusion: Consistently with other observational studies, our data show effectiveness of rituximab in reducing disease activity in patients with MS.

Zecca, C., Bovis, F., Novi, G., Capobianco, M., Lanzillo, R., Frau, J., et al. (2020). Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience. MULTIPLE SCLEROSIS, 26(12), 1519-1531 [10.1177/1352458519872889].

Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience

Salemi, Giuseppe;
2020-10-01

Abstract

Background: Rituximab, an anti-CD20 monoclonal antibody leading to B lymphocyte depletion, is increasingly used as an off-label treatment option for multiple sclerosis (MS). Objective: To investigate the effectiveness and safety of rituximab in relapsing-remitting (RR) and progressive MS. Methods: This is a multicenter, retrospective study on consecutive MS patients treated off-label with rituximab in 22 Italian and 1 Swiss MS centers. Relapse rate, time to first relapse, Expanded Disability Status Scale (EDSS) progression, incidence of adverse events, and radiological outcomes from 2009 to 2019 were analyzed. Results: A total of 355/451 enrolled subjects had at least one follow-up visit and were included in the outcome analysis. Annualized relapse rate significantly decreases after rituximab initiation versus the pre-rituximab start year in RRMS (from 0.86 to 0.09, p < .0001) and in secondary-progressive (SP) MS (from 0.34 to 0.06, p < .0001) and had a slight decrease in primary-progressive (PP) MS patients (from 0.12 to 0.07, p = 0.45). After 3 years from rituximab start, the proportion of patients with a confirmed EDSS progression was 14.6% in the RRMS group, 24.7% in the SPMS group, and 41.5% in the PPMS group. No major safety concerns arose. Conclusion: Consistently with other observational studies, our data show effectiveness of rituximab in reducing disease activity in patients with MS.
ott-2020
Settore MED/26 - Neurologia
Zecca, C., Bovis, F., Novi, G., Capobianco, M., Lanzillo, R., Frau, J., et al. (2020). Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience. MULTIPLE SCLEROSIS, 26(12), 1519-1531 [10.1177/1352458519872889].
File in questo prodotto:
File Dimensione Formato  
2020 Treatment of Multiple Sclerosis With Rituximab A Multicentric Italian-Swiss Experience.pdf

accesso aperto

Tipologia: Post-print
Dimensione 991.37 kB
Formato Adobe PDF
991.37 kB Adobe PDF Visualizza/Apri
zecca-et-al-2019-treatment-of-multiple-sclerosis-with-rituximab-a-multicentric-italian-swiss-experience.pdf

Solo gestori archvio

Tipologia: Versione Editoriale
Dimensione 978.18 kB
Formato Adobe PDF
978.18 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/584695
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 36
social impact